Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rocket Pharmaceuticals, Inc.

2.53
-0.0600-2.32%
Post-market: 2.550.0200+0.79%19:59 EDT
Volume:6.04M
Turnover:15.37M
Market Cap:272.58M
PE:-0.97
High:2.70
Open:2.58
Low:2.50
Close:2.59
Loading ...

Regenxbio Signs Royalty Deal Worth Up to $250 Million With Healthcare Royalty

MT Newswires Live
·
20 May

Chardan Ups Price Target on Rocket Pharmaceuticals to $46 From $45, Maintains Buy Rating

MT Newswires Live
·
16 May

Rocket Pharmaceuticals price target raised to $46 from $45 at Chardan

TIPRANKS
·
16 May

Scotiabank Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
16 May

Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
16 May

Stock Track | Rocket Pharmaceuticals Soars 5.20% on Promising Phase 1 Clinical Trial Results for RP-A601

Stock Track
·
16 May

BRIEF-Rocket Pharmaceuticals Presents Preliminary Data From Phase 1 Clinical Trial of RP-A601 For PKP2 Arrhythmogenic Cardiomyopathy At 28th Annual Meeting Of The American Society Of Gene And Cell Therapy

Reuters
·
16 May

Rocket Pharmaceuticals reports preliminary data from Phase 1 RP-A601 trial

TIPRANKS
·
16 May

Rocket Pharmaceuticals Presents Preliminary Data From Phase 1 Clinical Trial of Rp-a601 for Pkp2 Arrhythmogenic Cardiomyopathy at 28TH Annual Meeting of the American Society of Gene and Cell Therapy

THOMSON REUTERS
·
16 May

Rocket Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
12 May

Rocket Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
12 May

Chardan Adjusts Price Target on Rocket Pharmaceuticals to $45 From $54, Maintains Buy Rating

MT Newswires Live
·
12 May

Rocket Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
10 May

Rocket Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Rocket Pharmaceuticals Reports Q1 2025 Financial Results; Cash Position at $318.2 Million, Operational Runway Extended to Q4 2026

Reuters
·
09 May

Rocket Pharmaceuticals Q1 EPS $(0.56) Beats $(0.63) Estimate

Benzinga
·
09 May

BRIEF-Rocket Pharmaceuticals Q1 Basic EPS USD -0.56

Reuters
·
09 May

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

THOMSON REUTERS
·
09 May

Is Rocket Pharmaceuticals (NASDAQ:RCKT) In A Good Position To Deliver On Growth Plans?

Simply Wall St.
·
16 Apr

Rocket Pharmaceuticals CEO buys $101.6K in common stock

TIPRANKS
·
15 Apr